Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors
Ying Cheng, … , John K. Choi, Wei Tong
Ying Cheng, … , John K. Choi, Wei Tong
Published March 14, 2016
Citation Information: J Clin Invest. 2016;126(4):1267-1281. https://doi.org/10.1172/JCI81468.
View: Text | PDF
Research Article Oncology

LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors

  • Text
  • PDF
Abstract

Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk ALL commonly associated with alterations that affect the tyrosine kinase pathway, tumor suppressors, and lymphoid transcription factors. Loss-of-function mutations in the gene-encoding adaptor protein LNK (also known as SH2B3) are found in Ph-like ALLs; however, it is not clear how LNK regulates normal B cell development or promotes leukemogenesis. Here, we have shown that combined loss of Lnk and tumor suppressors Tp53 or Ink4a/Arf in mice triggers a highly aggressive and transplantable precursor B-ALL. Tp53–/–Lnk–/– B-ALLs displayed similar gene expression profiles to human Ph-like B-ALLs, supporting use of this model for preclinical and molecular studies. Preleukemic Tp53–/–Lnk–/– pro-B progenitors were hypersensitive to IL-7, exhibited marked self-renewal in vitro and in vivo, and were able to initiate B-ALL in transplant recipients. Mechanistically, we demonstrated that LNK regulates pro-B progenitor homeostasis by attenuating IL-7–stimuated JAK/STAT5 signaling via a direct interaction with phosphorylated JAK3. Moreover, JAK inhibitors were effective in prolonging survival of mice transplanted with Lnk–/–Tp53–/– leukemia. Additionally, synergistic administration of PI3K/mTOR and JAK inhibitors further abrogated leukemia development. Hence, our results suggest that LNK suppresses IL-7R/JAK/STAT signaling to restrict pro-/pre-B progenitor expansion and leukemia development, providing a pathogenic mechanism and a potential therapeutic approach for B-ALLs with LNK mutations.

Authors

Ying Cheng, Kudakwashe Chikwava, Chao Wu, Haibing Zhang, Anchit Bhagat, Dehua Pei, John K. Choi, Wei Tong

×

Figure 3

p53–/–Lnk–/– pro-B progenitors initiate B-ALL, and Lnk–/–p53–/– B leukemic blasts resemble human Ph-like ALL.

Options: View larger image (or click on image) Download as PowerPoint

p53–/–Lnk–/– pro-B progenitors initiate B-ALL, and Lnk–/–p53–/– B leuke...
(A) LOH of the Lnk allele in p53–/–Lnk+/– mice. B-ALL blasts and normal myeloid, T cells, and mature B cells were purified by flow cytometric sorting (left panels), and subjected to PCR analysis of Lnk gene status (top right panel). Various HSPC populations from p53–/–Lnk+/– mice were purified and subjected to PCR analysis for Lnk gene status (bottom right panel). LSK, HSPCs (Lin–Sca1+Kit+); LKS-, myeloid progenitors (Lin–Sca1–Kit+); CLPs, (Lin–IL-7R+Flt3+KitloSca1lo). (B) Kaplan-Meier curves show the survival of mice transplanted with 1,000 LSK cells from 2-month-old Lnk–/–, p53–/–, or p53–/–Lnk–/– preleukemic mice. P value found using log-rank t test. n = 5 mice per group. (C) Kaplan-Meier curves show the survival of mice transplanted with 100,000 pro-B cells from young preleukemic p53–/–Lnk–/– mice. P value found using log-rank t test. n = 6 mice per group. (D) Enrichment plots of GSEA analysis using Lnk–/–p53–/– B leukemic blasts (4 samples) versus control B progenitors (11 samples consist of 3 WT, 3 Lnk–/–, 3 p53–/–, and 2 preleukemic p53–/–Lnk–/– mice) express data against Ph-like B-ALL gene signature from the previous publication (6). NES, normalized enrichment score; FDR, false discovery rate.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts